ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia (EPICOR ASIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01361386
Recruitment Status : Completed
First Posted : May 26, 2011
Last Update Posted : June 16, 2014
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.

Condition or disease
Acute Coronary Syndrome

Study Type : Observational
Actual Enrollment : 13011 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia
Study Start Date : June 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Group/Cohort
1



Primary Outcome Measures :
  1. short- and long-term medication and treatment prescribed by physicians in real-life setting [ Time Frame: up to 3 years ]

Secondary Outcome Measures :
  1. clinical outcome (Cardiovascular events) [ Time Frame: up to 3 years ]
  2. cost of hospitalization [ Time Frame: up to 3 years ]
  3. quality of life (EQ-5D questionnaire) [ Time Frame: up to 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction (NSTEMI).
Criteria

Inclusion Criteria:

  • Written informed consent has been provided.
  • Diagnosis of STEMI, NSTEMI or UA
  • Hospitalization for the first time within 48 hours of onset of symptoms.

Exclusion Criteria:

  • UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
  • Current participation in a randomised interventional clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01361386


  Show 109 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Guy Yeoman AstraZeneca
Study Chair: Prof. Huo Yong Peking University 1st Hospital
Study Chair: Jayanti Visvanathan AstraZeneca

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01361386     History of Changes
Other Study ID Numbers: NIS-CAP-XXX-2011/1
First Posted: May 26, 2011    Key Record Dates
Last Update Posted: June 16, 2014
Last Verified: June 2014

Keywords provided by AstraZeneca:
Long-term follow up
Antithrombotic management patterns
Acute Coronary Syndrome
Asia
quality of life

Additional relevant MeSH terms:
Syndrome
Acute Coronary Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases